Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

hieved a partial response with a median response duration of 9 months.  An additional 6 patients receiving the combination (40%) achieved stable disease.  The combination was well tolerated with no unexpected safety events.

The investigators concluded that perifosine in combination with sorafenib has significant anti-lymphoma activity in relapsed/refractory HL, and that perifosine as a single agent induced prolonged responses in high-risk, heavily pretreated CLL patients.

Abstract # 1842:  "Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)"Study Background:  In this Phase 2 study, 12 patients with advanced CLL began treatment with single agent perifosine at 50 mg BID. Patients on study were heavily pre-treated having had a median of 4 prior lines of therapy with 75% of patients classified as Rai stage IV.

Results:  1 patient achieved a partial response (5 months on treatment) and 5 additional patients achieved stable disease (median duration of 4.25 months), for an overall 50% clinical benefit rate (PR + SD).  Perifosine was well tolerated with minimal dose modifications.

Abstract #3064: "Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed or Refractory Multiple Myeloma (MM)"Additionally, the final dataset from the Phase 1 study of perifosine + lenalidomide (Revlimid®) + dexamethasone was also presented during the ASH meeting.  The final data showed a 73% objective response rate (minimal response or better) with a 50% PR or better, a median Progression-Free Survival of 10.8 months, and a median duration for Overall Survival of 30.6 months.  The myeloma investigators concluded that perifosine in combination with lenalidomide + dexamethasone was well tolerated even at the highest doses used, and demonstrated encouraging clini
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Moerae ... developing novel therapeutics that target inflammation and fibrosis, ... , M.D., PhD, as Chief Medical Officer. ... clinical development strategy and programs, which include a ... inflammatory and fibrotic conditions.  Bill is an accomplished ...
(Date:7/6/2015)... July 6, 2015 Celtaxsys, Inc., a clinical ... those with rare and orphan inflammatory disease indications, announced ... Food and Drug Administration (FDA) to begin a Phase ... (CTX-4430), in adult CF patients in the US. The ... Europe will be filed soon after. This ...
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... Sept. 27 According to Millennium Research Group (MRG), the ... overall leader in the US ultrasound system market last year. ... and Siemens in the market, but it also earned a ... year. This diverse portfolio has enabled GE to maintain a ...
... SAN DIEGO, Sept. 27 CareFusion (NYSE: ... medical device company, has announced it has ... to market and sell innovative surgical scrub ... Triseptin® Water-Aided Surgical Scrub and Triseptin® Hand ...
Cached Medicine Technology:GE Healthcare Set to Take Share from Siemens and Philips in the $1.2 Billion US Ultrasound Market 2GE Healthcare Set to Take Share from Siemens and Philips in the $1.2 Billion US Ultrasound Market 3CareFusion Expands Skin Antisepsis Portfolio 2CareFusion Expands Skin Antisepsis Portfolio 3CareFusion Expands Skin Antisepsis Portfolio 4CareFusion Expands Skin Antisepsis Portfolio 5
(Date:7/5/2015)... ... 2015 , ... Doctors at the Swedish Cancer Institute in Seattle, Washington say ... the outlook for people with pleural mesothelioma. Surviving Mesothelioma has just posted the full ... five mesothelioma patients treated with 25Gy of radiation over five days just prior to ...
(Date:7/4/2015)... ... ... hacker gains access to someone’s email account, it can lead to all sorts of trouble, ... FTC issued a scam alert about a social engineering scam which cons a target ... by the hacker. All they have to do is click for a password reset ...
(Date:7/3/2015)... ... July 03, 2015 , ... On June 30th SEO ... SEO training system called "Page One Engine" . The program, which has ... glowing reviews from several well-known marketers. HonestyFirstReviews.com's Tiffany Hendricks has joined the party, ...
(Date:7/3/2015)... ... 03, 2015 , ... B. E. Smith, the only full-service ... a national president recruitment for Regional Care, Inc. in Scottsbluff, Neb. ... Smith has recently placed more than 1,000 healthcare executives into organizations. , ...
(Date:7/3/2015)... St. Louis, MO (PRWEB) , ... July 03, 2015 , ... ... new responsive website to replace their existing Talcum Powder Cancer Lawsuit Center website. Just ... for talcum powder lawsuit news , offering timely lawsuit updates and ovarian cancer ...
Breaking Medicine News(10 mins):Health News:New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:Page One Engine - Review Of Dori Friend's SEO Training Course Released 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3
... University,s Slone Epidemiology Center have found that in a given ... than 4 million are taking them regularly (at least five ... findings appear in the August 31 issue of the journal ... the treatment of moderate to severe pain and are among ...
... 2008 Two new studies show that migraine headaches ... condition is frequently underdiagnosed. The studies, appearing in ... Society, examine the incidence among soldiers within 10 days ... , as well as U.S. Army officer trainees. ...
... Aug. 26 Buying travel insurance can be,complicated, ... the leading,online travel insurance comparison site, coverage is ... a world-class Customer Care Team,providing a level of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ), Providing access ...
... Stanford University School of Medicine are shedding light on how ... caused by an autoimmune attack on the pancreas, but the ... new study in mice implicates the immune signal interferon-alpha as ... sugar metabolism and make patients dependent on lifelong insulin injections. ...
... by government-sponsored programs, Census Bureau reports , , TUESDAY, ... without health insurance dropped by more than 1 million ... years, U.S. Census Bureau officials announced Tuesday. , The ... number of children getting health insurance through government-funded programs. ...
... heard on both the SIRIUS and XM services on SIRIUS, Hits 1 SIRIUS ... XM ... channel 24, NEW YORK, Aug. 26 ... Cancer (SU2C) Campaign to broadcast its "Just Stand Up" national,fundraising event live on ...
Cached Medicine News:Health News:Study examines use of opioids 2Health News:Army personnel show increased risk for migraine 2Health News:InsureMyTrip.com's Expert Customer Care Team Takes the Guesswork Out of Buying Travel Insurance 2Health News:Early trigger for type-1 diabetes found in mice, Stanford scientists report 2Health News:Early trigger for type-1 diabetes found in mice, Stanford scientists report 3Health News:Number of Uninsured Americans Drops 2Health News:Number of Uninsured Americans Drops 3Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 2Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 3Health News:SIRIUS XM Radio Joins Stand Up To Cancer Campaign with Live Broadcast of Star-Studded 'Just Stand Up' Fundraising Event on September 5 4
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... incorporate a layered design unique in the ... to prevent stray electrosurgical burns along the ... failure or capacitive coupling; a well-documented patient ... all AEM Instruments provides a neutral return ...
Medicine Products: